73781-91-6

Usage

Uses

Used in Chemical Synthesis:
Methyl 6-chloronicotinate is used as a building block in chemical synthesis for the development of various products. Its unique structure allows it to be a valuable component in the creation of new compounds and materials.
Used in Agricultural Analysis:
In the agricultural industry, Methyl 6-chloronicotinate is utilized in the determination of Acetamiprid (A150800) and its metabolites in crops and soil. This application is crucial for ensuring the safety and quality of agricultural products, as well as monitoring the environmental impact of pesticides and their breakdown products.

InChI:InChI=1/C7H6ClNO2/c1-11-7(10)5-2-3-6(8)9-4-5/h2-4H,1H3

Upstream product

• 5006-66-6 6-hydroxy-3-pyridinecarboxylic acid 
• 3719-45-7 1-methyl-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid 
• 67-56-1 methanol 
• 33225-73-9 6-nitronicotinic acid 
• 186581-53-3 diazomethane 
• 5326-23-8 6-Chloro-3-pyridinecarboxylic acid 
• 26218-80-4 6-methoxy-nicotinic acid methyl ester 
• 23100-12-1 6-chloronicotinylaldehyde 
• 1074-38-0 5-methyl-2-nitropyridine 
• 74-88-4 methyl iodide 
• 21543-49-7 2-Chloro-5-hydroxymethylpyridine 
• 17874-79-2 pyridine-2,5-dicarboxylic acid 5-methyl ester 
• 365413-29-2 6-chloro-5-iodonicotinic acid methyl ester 
• 885950-46-9 6-hydroxy-5-iodonicotinic acid methyl ester 

Downstream Products

• 68700-93-6 2-chloro-5-isopropylpyridine 
• 4634-13-3 methyl 6-phenylnicotinate 
• 58792-53-3 2,2'-bipyridine-5-carboxylic acid methyl ester 
• 908297-79-0 6-naphthalen-1-yl-nicotinic acid methyl ester 
• 331745-78-9 6-[2-(5-Methyl-2-phenyl-oxazol-4-yl)-ethoxy]-nicotinic acid methyl ester 
• 220339-96-8 5-(aminomethyl)-2,2′-bipyridine 
• 63056-20-2 2-phenyl-5-pyridinecarboxaldehyde 
• 4634-09-7 2-phenyl-5-hydroxymethylpyridine 
• 179055-41-5 Cycloheptyl-(6-phenyl-pyridin-3-ylmethyl)-amine 
• 132144-03-7 2-(1-piperazinyl)-5-pyridinecarboxylic acid methyl ester 
• 1221403-85-5 6-(2-chloro-phenyl)-nicotinic acid methyl ester 
• 832114-28-0 6-(5-Cyclopropylcarbamoyl-2-methyl-phenyl)-nicotinic acid methyl ester 
• 132546-81-7 methyl 6-morpholinonicotinate 
• 356058-34-9 methyl 6-(4-(trifluoromethyl)phenyl)nicotinate 

Relevant academic research and scientific papers

Rhenium and Technetium-oxo Complexes with Thioamide Derivatives of Pyridylhydrazine Bifunctional Chelators Conjugated to the Tumour Targeting Peptides Octreotate and Cyclic-RGDfK

This research aimed to develop new tumor targeted theranostic agents taking advantage of the similarities in coordination chemistry between technetium and rhenium. A γ-emitting radioactive isotope of technetium is commonly used in diagnostic imaging, and there are two β- emitting radioactive isotopes of rhenium that have the potential to be of use in radiotherapy. Variants of the 6-hydrazinonicotinamide (HYNIC) bifunctional ligands have been prepared by appending thioamide functional groups to 6-hydrazinonicotinamide to form pyridylthiosemicarbazide ligands (SHYNIC). The new bidentate ligands were conjugated to the tumor targeting peptides Tyr3-octreotate and cyclic-RGD. The new ligands and conjugates were used to prepare well-defined {M=O}3+ complexes (where M = 99mTc or natRe or 188Re) that feature two targeting peptides attached to the single metal ion. These new SHYNIC ligands are capable of forming well-defined rhenium and technetium complexes and offer the possibility of using the 99mTc imaging and 188/186Re therapeutic matched pairs.

Synthesis method of methyl 6-methoxypyridin-3-formate

The invention discloses a synthesis method of methyl 6-methoxypyridin-3-formate, which comprises the following steps: carrying out esterification reaction on 2-chloronicotinic acid serving as a main raw material, methanol serving as a solvent and a methylation reagent and concentrated sulfuric acid serving as a catalyst to prepare an intermediate, the intermediate takes methanol as a solvent and sodium methoxide as alkali to replace halogen to obtain methyl 6-methoxypyridin-3-formate, and the whole process has the advantages of simple and accessible raw materials, simple and feasible operationand favorable economic benefit.

Palladium-Catalyzed Chlorocarbonylation of Aryl (Pseudo)Halides Through In Situ Generation of Carbon Monoxide

An efficient palladium-catalyzed chlorocarbonylation of aryl (pseudo)halides that gives access to a wide range of carboxylic acid derivatives has been developed. The use of butyryl chloride as a combined CO and Cl source eludes the need for toxic, gaseous carbon monoxide, thus facilitating the synthesis of high-value products from readily available aryl (pseudo)halides. The combination of palladium(0), Xantphos, and an amine base is essential to promote this broadly applicable catalytic reaction. Overall, this reaction provides access to a great variety of carbonyl-containing products through in situ transformation of the generated aroyl chloride. Combined experimental and computational studies support a reaction mechanism involving in situ generation of CO.

Transition-metal-free decarboxylative halogenation of 2-picolinic acids with dihalomethane under oxygen conditions

A convenient and efficient method for the synthesis of 2-halogen-substituted pyridines is described. The decarboxylative halogenation of 2-picolinic acids with dihalomethane proceeded smoothly via N-chlorocarbene intermediates to afford 2-halogen-substituted pyridines in satisfactory to excellent yields under transition-metal-free conditions. This new type of decarboxylative halogenation is operationally simple and exhibits high functional-group tolerance.

THERAPEUTIC METHODS AND COMBINATIONS

Combinations comprising substituted 1-hydroxypyridine-2(1H)-thiones or a pharmaceutically acceptable salt thereof and an antibacterial agent are disclosed. Also disclosed are therapeutic methods comprising the administration of a substituted 1-hydroxypyri

MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt (s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present invention describes the preparation, pharmaceutical composition and the use of compound formula (I).

Preparation method of non-transition metal-catalyzed 2-halogenated pyridine compound

The invention provides a preparation method of a non-transition metal-catalyzed 2-halogenated pyridine compound. The 2-halogenated pyridine compound is an important component of many medicines and bioactive molecules and has important application in the fields of organic synthesis, medicinal chemistry and the like and wide market prospects. The invention relates to the preparation method of the non-transition metal-catalyzed 2-halogenated pyridine compound. According to the method, pyridine-2-carboxylic acid, derivatives of the pyridine-2-carboxylic acid, NaF, KF, CsF, TBAF, NaCl, KCl, CsCl, TBAC, NCS, NaBr, KBr, CsBr, Br2, TBAB, NBS, NaI, KI, CsI, I2 and NIS are used as raw materials, and under the presence of base and an accelerant and mild conditions, the 2-halogenated pyridine compoundis synthesized. The method has the advantages that the steps are simple, the raw materials are easy to obtain, the reaction conditions are mild and the like; the method has great use value and socialand economic benefits.

Discovery of New Potential Anti-Infective Compounds Based on Carbonic Anhydrase Inhibitors by Rational Target-Focused Repurposing Approaches

In academia, compound recycling represents an alternative drug discovery strategy to identify new pharmaceutical targets from a library of chemical compounds available in house. Herein we report the application of a rational target-based drug-repurposing approach to find diverse applications for our in-house collection of compounds. The carbonic anhydrase (CA, EC 4.2.1.1) metalloenzyme superfamily was identified as a potential target of our compounds. The combination of a thoroughly validated docking screening protocol, together with in vitro assays against various CA families and isoforms, allowed us to identify two unprecedented chemotypes as CA inhibitors. The identified compounds have the capacity to preferentially bind pathogenic (bacterial/protozoan) CAs over human isoforms and represent excellent hits for further optimization in hit-to-lead campaigns.

1-substituted 4-arylpiperazine as kappa opioid receptor antagonists

Provided are compounds represented by the formula: where R, Y3, R1, R2, R3, R4, R6, G, R7, E1, E2, A, B, W, X, Y and Z are as defined herein.

Synthesis and antiproliferative activity of novel 4-substituted-phenoxy-benzamide derivatives

A series of novel 4-substituted-phenoxy-benzamide derivatives bearing an aryl cycloaliphatic amine moiety were synthesized and evaluated for antiproliferative activity against SW620, HT29 and MGC803 cancer cell lines in vitro. The pharmacological data demonstrated that the majority of target compounds exhibited moderate efficacy in HT29 and MGC803 cell lines. Compound 10c showed promising inhibition of hedgehog (Hh) signaling pathway in an Hh-related assay. In addition, the superposition pattern of 10c showed a good fit for a pharmacophoric model generated by Hh inhibitors and provided a basis for further structural optimization.